Neos Therapeutics, Inc. (NEOS) Receives New Coverage from Analysts at Cantor Fitzgerald

Equities researchers at Cantor Fitzgerald assumed coverage on shares of Neos Therapeutics, Inc. (NASDAQ:NEOS) in a research note issued on Monday, July 31st, MarketBeat Ratings reports. The brokerage set an “overweight” rating and a $20.00 price target on the stock. Cantor Fitzgerald’s target price suggests a potential upside of 177.78% from the stock’s previous close. Cantor Fitzgerald also issued estimates for Neos Therapeutics’ FY2017 earnings at ($3.00) EPS and FY2018 earnings at ($1.47) EPS.

Several other research analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of Neos Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th. ValuEngine upgraded shares of Neos Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Tuesday, June 20th. Finally, BMO Capital Markets restated an “outperform” rating and set a $15.00 price target on shares of Neos Therapeutics in a research report on Tuesday, June 20th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $14.00.

Shares of Neos Therapeutics (NEOS) traded up 2.13% during midday trading on Monday, hitting $7.20. The company’s stock had a trading volume of 465,979 shares. Neos Therapeutics has a 52-week low of $4.85 and a 52-week high of $9.60. The firm’s market cap is $196.99 million. The stock’s 50 day moving average is $6.97 and its 200-day moving average is $6.96.

Neos Therapeutics (NASDAQ:NEOS) last released its quarterly earnings results on Tuesday, August 8th. The company reported ($0.83) earnings per share for the quarter, hitting the consensus estimate of ($0.83). The firm had revenue of $4.91 million for the quarter. Neos Therapeutics had a negative net margin of 511.74% and a negative return on equity of 889.59%. Equities analysts predict that Neos Therapeutics will post ($3.20) EPS for the current fiscal year.

WARNING: “Neos Therapeutics, Inc. (NEOS) Receives New Coverage from Analysts at Cantor Fitzgerald” was reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.com-unik.info/2017/08/11/cantor-fitzgerald-initiates-coverage-on-neos-therapeutics-inc-neos-updated.html.

A number of institutional investors have recently added to or reduced their stakes in NEOS. Hunter Associates Investment Management LLC bought a new position in Neos Therapeutics during the first quarter worth about $360,000. Russell Investments Group Ltd. acquired a new position in shares of Neos Therapeutics during the fourth quarter worth $545,000. Teachers Advisors LLC increased its position in shares of Neos Therapeutics by 16.3% in the fourth quarter. Teachers Advisors LLC now owns 25,496 shares of the company’s stock worth $149,000 after buying an additional 3,572 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of Neos Therapeutics by 130.3% in the first quarter. Wells Fargo & Company MN now owns 48,030 shares of the company’s stock worth $346,000 after buying an additional 27,174 shares in the last quarter. Finally, Sheaff Brock Investment Advisors LLC acquired a new position in shares of Neos Therapeutics during the first quarter worth $216,000. 34.45% of the stock is owned by institutional investors.

Neos Therapeutics Company Profile

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

What are top analysts saying about Neos Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Neos Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit